Kayser, Frank
Nurix (United States)
3 papers on CoChat
Most cited papers
- Verified
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2–p53 Inhibitor in Clinical Development
Sun, D., Li, Z., Rew, Y., Gribble, M., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chen, X., Chow, D., et al. (2014) · Journal of Medicinal Chemistry
Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity
Cited by 290
- Verified
Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction
Simonetta, K. R., Taygerly, J., Boyle, K., Basham, S. E., Padovani, C., Lou, Y., Cummins, T. J., Yung, S. L., von Soly, S. K., Kayser, F., et al. (2019) · Nature Communications
Protein Degradation and InhibitorsUbiquitin and proteasome pathways
Cited by 217
- Verified
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry
Cancer-related Molecular PathwaysHeterocyclic Compound Synthesis and Bioactivity
Cited by 82
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free